ArticleMolecular psychiatry2016
A critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior.
Article in Molecular psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- The role of vascular endothelial growth factor (VEGF) in major depressive disorder: an update meta-analysis.BMC psychiatry · 2026Pooled it
- Transcriptome of the human C2 dorsal root ganglia in C1-2 arthrodesis surgery: insight for neck pain.Brain : a journal of neurology · 2026Article
- Dihydromyricetin Modulates Neuropathic Pain and Depression: A Correlation with Hippocampal Vascular Endothelial Growth Factor in Mice.Journal of inflammation research · 2026Article
- Effects of esketamine on electrophysiology and metabolic reprogramming in brain organoids: insights into antidepressant mechanisms.Molecular psychiatry · 2025Article
- MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity.Cell discovery · 2025Article
- The association between physical activity and depression among weekend catch-up sleepers: results from NHANES 2021-2023.BMC psychiatry · 2025Article
- Exercise Delays Brain Ageing Through Muscle-Brain Crosstalk.Cell proliferation · 2025Review
- ACSL3 is a promising therapeutic target for alleviating anxiety and depression in Alzheimer's disease.GeroScience · 2025Article
- Beyond vessels: unraveling the impact of VEGFs on neuronal functions and structure.Journal of biomedical science · 2025Review
- Exercise epigenetics is fueled by cell bioenergetics: Supporting role on brain plasticity and cognition.Free radical biology & medicine · 2024Review
- Article
- Major depressive disorder: hypothesis, mechanism, prevention and treatment.Signal transduction and targeted therapy · 2024Review
- A novel peptide derived from vascular endothelial growth factor prevents amyloid beta aggregation and toxicity.Aging cell · 2023Article
- Article
- Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD.NPJ Parkinson's disease · 2023Article
- Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain.The journal of pain · 2023Article
- Regulation of AMPA receptor trafficking by secreted protein factors.Frontiers in cellular neuroscience · 2023Review
- Neurotrophic basis to the pathogenesis of depression and phytotherapy.Frontiers in pharmacology · 2023Review
- Dihydromyricetin Attenuates Depressive-like Behaviors in Mice by Inhibiting the AGE-RAGE Signaling Pathway.Cells · 2022Article
- Exercise Regulates the Lactate Receptor HCAR1 and ERK1/2-PI3K/Akt Pathways to Promote Cerebral Angiogenesis.Iranian journal of public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor (VEGF) is known to be required for the action of antidepressant therapies but its impact on brain synaptic function is poorly characterized. Using a combination of electrophysiological, single-molecule imaging and conditional transgenic approaches, we identified the molecular basis of the VEGF effect on synaptic transmission and plasticity. VEGF increases the postsynaptic responses mediated by the N-methyl-D-aspartate type of glutamate receptors (GluNRs) in hippocampal neurons. This is concurrent with the formation of new synapses and with the synaptic recruitment of GluNR expressing the GluN2B subunit (GluNR-2B). VEGF induces a rapid redistribution of GluNR-2B at synaptic sites by increasing the surface dynamics of these receptors within the membrane. Consistently, silencing the expression of the VEGF receptor 2 (VEGFR2) in neural cells impairs hippocampal-dependent synaptic plasticity and consolidation of emotional memory. These findings demonstrated the direct implication of VEGF signaling in neurons via VEGFR2 in proper synaptic function. They highlight the potential of VEGF as a key regulator of GluNR synaptic function and suggest a role for VEGF in new therapeutic approaches targeting GluNR in depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.